| One-year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab |
|
European Journal of Haematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Frequency and perturbations of various peripheral blood cell populations before and after eculizumab treatment in paroxysmal nocturnal hemoglobinuria |
|
Blood, cells, molecules & diseases |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Survival following relapse after allogeneic hematopoietic cell transplantation for acute leukemia and myelodysplastic syndromes |
|
Hematology/oncology and stem cell therapy |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
| Existing agents, novel agents, or transplantation for high-risk MDS |
|
Hematology. American Society of Hematology. Education Program |
Myelodysplastic Syndromes (MDS) |
| Therapy for lower-risk MDS |
|
Hematology. American Society of Hematology. Education Program |
Myelodysplastic Syndromes (MDS) |
| Patient stratification in myelodysplastic syndromes: how a puzzle may become a map |
|
Hematology. American Society of Hematology. Education Program |
Myelodysplastic Syndromes (MDS) |
| Outpatient transfusions for myelodysplastic syndromes |
|
Hematology. American Society of Hematology. Education Program |
Myelodysplastic Syndromes (MDS) |
| Parsing the Paradox of Myelodysplastic Syndromes |
|
Journal of clinical oncology: official journal of the American Society Clinical Oncologysd |
Myelodysplastic Syndromes (MDS) |
| Randomized trials with checkpoint inhibitors in acute myeloid leukaemia and myelodysplastic syndromes: What have we learned so far and where are we heading? |
|
Best practice & research. Clinical haematology |
Myelodysplastic Syndromes (MDS) |
| Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis- stimulating agents |
|
Leukemia Research |
Myelodysplastic Syndromes (MDS) |
